Ionis Pharmaceuticals Inc
IONS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000874015
In the last 90 days, Ionis Pharmaceuticals Inc insiders filed 1 open-market purchase and 4 sales; 515 institutions reported holding it in 13F filings for Q2 2026, worth $14.3B in total; ARK Invest is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Ionis Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $1.06M in total
- Open-market sells
- 4 filings
- 4 insiders, $3.55M in total
- Insiders trading
- 5
- Net value
- −$2.49M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Ionis Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Bennett C Frank | EVP, Chief Scientific Officer | 60,128 | Sep 2, 2026 | 8 |
| O'Neil Patrick R. | EVP CLO & General Counsel | 59,205 | Sep 2, 2026 | 10 |
| Monia Brett P | Chief Executive Officer | 242,760 | Sep 2, 2026 | 10 |
| Birchler Brian | EVP, Corp and Development Ops | 102,883 | Sep 2, 2026 | 8 |
| Hayden Michael R | Director | 24,000Indirect | Jul 31, 2026 | 2 |
| Reikes Peter N | Director | 14,222 | Jul 17, 2026 | 2 |
| Hantson Ludwig | Director | – | Jul 17, 2026 | 2 |
| Herman Joan E | Director | 51,306 | Jul 17, 2026 | 3 |
| Berthelsen Spencer R | Director | 161,233 | Jul 17, 2026 | 4 |
| Diaz Allene M. | Director | 3,811 | Jul 9, 2026 | 3 |
| Kordasiewicz Holly B. | EVP, Chief Development Officer | 22,096 | Jul 9, 2026 | 4 |
| Yang Michael J. | Director | 7,940 | Jul 6, 2026 | 2 |
| Loscalzo Joseph | Director | 36,330 | Jul 6, 2026 | 4 |
| Klein Joseph III | Director | 11,014 | Jul 6, 2026 | 5 |
| Baroldi Joseph | EVP, Chief Business Officer | 4,669Indirect | Jun 30, 2026 | 9 |
| Schneider Eugene | EVP, Chf Clinical Develop Ofcr | 77,114 | Jun 30, 2026 | 5 |
| Swayze Eric | EVP Research | 21,759 | Jun 26, 2026 | 9 |
| Parshall B Lynne | Director | 51,344 | Apr 17, 2026 | 3 |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | 23,713 | Apr 17, 2026 | 4 |
| Devers Shannon L. | EVP, Chief Human Resources Ofc | 16,348 | Apr 2, 2026 | 8 |
| Hougen Elizabeth L | EVP, Finance & CFO | 82,660 | Mar 18, 2026 | 5 |
| Wender Joseph H | Director | 36,035Indirect | Dec 3, 2025 | 4 |
| Geary Richard S | EVP, Chief Development Officer | 59,657 | Nov 7, 2025 | 3 |
| Cadoret-Manier Onaiza | EVP,Chf GL Pdt Str & Oper Ofc | 35,788 | Sep 4, 2024 | 0 |
| Muto Frederick T | Director | 59,597 | Jul 19, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 24, 2023 (view filing) | May 22 | 2 days | Monia Brett PChief Executive Officer | SSale | −4.93K | $40.14 | −$197.9K | −3.4%140.4K after | 2 lots10b5-1 |
| Apr 19, 2023 (view filing) | Apr 18 | 1 day | Birchler BrianEVP, Corp and Development Ops | SSale | −672 | $36.50 | −$24.5K | −1.8%36.5K after | |
| Apr 19, 2023 (view filing) | Apr 18 | 1 day | Cadoret-Manier OnaizaEVP, Chf GL Pdt Str & Oper Ofc | SSale | −2.58K | $36.50 | −$94.2K | −9.6%24.3K after | |
| Apr 19, 2023 (view filing) | Apr 18 | 1 day | Baroldi JosephEVP, Chief Business Officer | SSale | −3.88K | $36.50 | −$141.6K | −26.8%10.6K after | |
| Feb 7, 2023 (view filing) | Feb 6 | 1 day | Swayze EricEVP Research | SSale | −1.81K | $40.79 | −$74.0K | −5.4%31.9K after | |
| Feb 7, 2023 (view filing) | Feb 6 | 1 day | Schneider EugeneEVP, Chf Clinical Develop Ofcr | SSale | −1.41K | $40.67 | −$57.5K | −5.4%24.9K after | |
| Feb 7, 2023 (view filing) | Feb 6 | 1 day | O'Neil Patrick R.EVP CLO & General Counsel | SSale | −1.92K | $40.86 | −$78.5K | −4.4%41.6K after | |
| Feb 7, 2023 (view filing) | Feb 6 | 1 day | Monia Brett PChief Executive Officer | SSale | −24.7K | $40.69 | −$1.00M | −14.5%145.3K after | |
| Feb 7, 2023 (view filing) | Feb 6 | 1 day | Hougen Elizabeth LEVP, Finance & CFO | SSale | −2.08K | $40.59 | −$84.4K | −2.7%75.5K after | |
| Feb 7, 2023 (view filing) | Feb 6 | 1 day | Geary Richard SEVP, Chief Development Officer | SSale | −1.92K | $40.66 | −$78.1K | −2.6%72.4K after | |
| Feb 7, 2023 (view filing) | Feb 6 | 1 day | Cadoret-Manier OnaizaEVP, Chf GL Pdt Str & Oper Ofc | SSale | −1.45K | $40.66 | −$59.0K | −6.4%21.2K after | |
| Feb 7, 2023 (view filing) | Feb 6 | 1 day | Bennett C FrankEVP, Chief Scientific Officer | SSale | −1.81K | $40.57 | −$73.6K | −2.5%69.7K after | |
| Feb 2, 2023 (view filing) | Jan 30-31 | 3 daysLate | O'Neil Patrick R.EVP CLO & General Counsel | SSale | −9.00K | $39.57 | −$356.1K | −18.5%39.7K after | 2 lots |
| Jan 19, 2023 (view filing) | Jan 18 | 1 day | Swayze EricEVP Research | SSale | −5.63K | $39.74 | −$223.8K | −15.8%30.0K after | |
| Jan 19, 2023 (view filing) | Jan 18 | 1 day | Schneider EugeneEVP, Chf Clinical Develop Ofcr | SSale | −4.75K | $39.57 | −$188.0K | −17.5%22.3K after | |
| Jan 19, 2023 (view filing) | Jan 18 | 1 day | O'Neil Patrick R.EVP CLO & General Counsel | SSale | −7.84K | $39.49 | −$309.4K | −13.9%48.7K after | |
| Jan 19, 2023 (view filing) | Jan 18 | 1 day | Monia Brett PChief Executive Officer | SSale | −25.1K | $39.49 | −$989.9K | −17.2%120.9K after | |
| Jan 19, 2023 (view filing) | Jan 18 | 1 day | Hougen Elizabeth LEVP, Finance & CFO | SSale | −8.28K | $39.70 | −$328.7K | −10.1%73.4K after | |
| Jan 19, 2023 (view filing) | Jan 18 | 1 day | Geary Richard SEVP, Chief Development Officer | SSale | −7.87K | $39.57 | −$311.5K | −10.0%70.5K after | |
| Jan 19, 2023 (view filing) | Jan 18 | 1 day | Cadoret-Manier OnaizaEVP, Chf GL Pdt Str & Oper Ofc | SSale | −3.75K | $39.55 | −$148.2K | −16.8%18.5K after | |
| Jan 19, 2023 (view filing) | Jan 18 | 1 day | Bennett C FrankEVP, Chief Scientific Officer | SSale | −6.98K | $38.89 | −$271.4K | −9.3%67.9K after | |
| Jan 19, 2023 (view filing) | Jan 18 | 1 day | Baroldi JosephEVP, Chief Business Officer | SSale | −375 | $39.79 | −$14.9K | −30.6%851 after | |
| Jan 18, 2023 (view filing) | Jan 17 | 1 day | Klein Joseph IIIDirector | SSale | −2.00K | $40.00 | −$80.0K | −10.6%16.8K after | |
| Sep 12, 2022 (view filing) | Sep 8 | 4 days | Swayze EricEVP Research | SSale | −460 | $44.55 | −$20.5K | −2.3%19.9K after | |
| Aug 9, 2022 (view filing) | Aug 5 | 4 days | Swayze EricEVP Research | SSale | −1 | $45.20 | −$45.2 | 0.0%20.4K after | |
| Jul 19, 2022 (view filing) | Jul 15 | 4 days | Klein Joseph IIIDirector | SSale | −1.33K | $38.24 | −$51.0K | −6.6%18.8K after | 2 lots |
| Apr 25, 2022 (view filing) | Apr 21 | 4 days | Swayze EricEVP Research | SSale | −378 | $44.15 | −$16.7K | −1.8%20.4K after | |
| Apr 14, 2022 (view filing) | Apr 12 | 2 days | O'Neil Patrick R.EVP CLO & General Counsel | SSale | −6.79K | $40.06 | −$272.1K | −16.4%34.5K after | |
| Apr 5, 2022 (view filing) | Apr 1 | 4 days | Monia Brett PChief Executive Officer | SSale | −355 | $37.49 | −$13.3K | −0.4%88.7K after | |
| Jul 19, 2021 (view filing) | Jul 15 | 4 days | Klein Joseph IIIDirector | SSale | −4.33K | $35.30 | −$153.0K | −19.3%18.1K after |